spiraprilat has been researched along with enalapril in 15 studies
| Studies (spiraprilat) | Trials (spiraprilat) | Recent Studies (post-2010) (spiraprilat) | Studies (enalapril) | Trials (enalapril) | Recent Studies (post-2010) (enalapril) |
|---|---|---|---|---|---|
| 20 | 7 | 0 | 6,311 | 1,924 | 859 |
| Protein | Taxonomy | spiraprilat (IC50) | enalapril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.3536 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2.7083 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 1.2 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.14 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 11 (73.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennion, C; Brown, RC; Cook, AR; Manners, CN; Payling, DW; Robinson, DH | 1 |
| Baum, T; Gold, EH; McNamara, P; Neustadt, BR; Smith, EM; Swiss, GF; Sybertz, EJ | 1 |
| Cushman, DW; DeForrest, JM; Duggan, M; Karanewsky, DS; Krapcho, J; Powell, JR; Rovnyak, G; Schwartz, J; Spitzmiller, ER; Turk, C | 1 |
| Gerbeau, C; Holt, DW; Hossein-Nia, M; Surve, AH; Weglein, R | 1 |
| Antonellis, A; Pula, K; Sybertz, EJ; Watkins, RW | 1 |
| Imai, S; Ishihara, T; Nakazawa, M; Okuhira, M; Takahashi, Y | 1 |
| Haufe, CC; Jansa, U; Sierakowski, B; Stein, G | 1 |
| Elliott, HL; Grass, P; Guitard, C; Meredith, PA | 1 |
| Grass, P; Haufe, CC; Jansa, U; Sierakowski, B; Stein, G; Weidinger, G | 1 |
| Duchiez, J; Guitard, C; Safar, ME; Sassano, P; Tzincoca, C | 1 |
| Gerbeau, C; Grass, P; Kutz, K | 1 |
| Grass, P; Krähenbühl, S; Kutz, K; Reichen, J; Surve, A | 1 |
| Bellissant, E; Chau, NP; Gerbeau, C; Giudicelli, JF; Richard, C; Thuillez, C | 1 |
| Hayduk, K; Kraul, H | 1 |
| Amschler, S; Schäfer, HF; Schulz, HU; Schürer, M | 1 |
1 review(s) available for spiraprilat and enalapril
| Article | Year |
|---|---|
Efficacy and safety of spirapril in mild-to-moderate hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Interactions; Enalapril; Humans; Hypertension; Prodrugs | 1999 |
6 trial(s) available for spiraprilat and enalapril
| Article | Year |
|---|---|
[Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Enalapril; Female; Humans; Hypertension; Kidney Failure, Chronic; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged | 1994 |
Pharmacokinetics of spirapril in renal impairment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Creatinine; Enalapril; Humans; Hypertension; Kidney Diseases; Single-Blind Method | 1994 |
Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Enalapril; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Regression Analysis; Single-Blind Method | 1994 |
Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Determination; Drug Administration Schedule; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System | 1994 |
Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.
Topics: Administration, Oral; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Enalapril; Female; Glycogen Storage Disease; Half-Life; Hemodynamics; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Diseases; Male; Middle Aged; Pulse | 1993 |
Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Enalapril; Heart Failure; Hemodynamics; Humans; Middle Aged; Models, Biological; Peptidyl-Dipeptidase A; Pulmonary Circulation; Pulmonary Wedge Pressure; Regional Blood Flow; Vascular Resistance | 1997 |
8 other study(ies) available for spiraprilat and enalapril
| Article | Year |
|---|---|
Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bile; Drug Design; Indicators and Reagents; Male; Metabolic Clearance Rate; Models, Molecular; Molecular Conformation; Molecular Structure; Rats; Structure-Activity Relationship; Thiadiazoles; X-Ray Diffraction | 1991 |
Angiotensin converting enzyme inhibitors: spirapril and related compounds.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Chemical Phenomena; Chemistry; Dogs; Enalapril; Male; Phenylbutyrates; Rats; Rats, Inbred Strains; Spiro Compounds | 1989 |
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Enalapril; Enalaprilat; Kinetics; Male; Phosphinic Acids; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1988 |
Radioimmunoassays for spirapril and its active metabolite spiraprilate: performance and application.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antibody Specificity; Buffers; Charcoal; Cross Reactions; Dextrans; Enalapril; Humans; Quality Control; Radioimmunoassay; Reference Standards; Serum Albumin, Bovine | 1992 |
Effects of spiraprilic acid, an angiotensin converting enzyme inhibitor, on large artery compliance in anesthetized dogs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Compliance; Dogs; Drug Interactions; Enalapril; Enalaprilat; Female; Hemodynamics; Hydrochlorothiazide; Male; Phenylbutyrates; Prodrugs; Spiro Compounds; Vascular Resistance | 1987 |
Effects of spiraprilat, an angiotensin-converting enzyme inhibitor, on anesthetized dogs in a new model of acute left ventricular failure.
Topics: Adenosine Triphosphate; Anesthesia; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Coronary Vessels; Disease Models, Animal; Dogs; Enalapril; Heart Failure; Lactates; Lactic Acid; Methoxamine; Microspheres; Myocardium; Oxygen Consumption; Phosphocreatine; Vascular Resistance; Ventricular Function, Left | 1993 |
Spirapril: pharmacokinetic properties and drug interactions.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enalapril; Humans; Kidney Diseases; Liver Diseases; Reference Values | 1994 |
Simultaneous determination of spirapril and spiraprilat in plasma by capillary gas chromatography-mass spectrometry.
Topics: Angiotensin-Converting Enzyme Inhibitors; Enalapril; Freezing; Gas Chromatography-Mass Spectrometry; Humans; Indicators and Reagents; Reference Standards; Reproducibility of Results; Solutions | 2003 |